AstraZeneca and the anticancer drug imifinge are subject to priority review by the US FDA

8/15/2024 8:23 PM GMT+9 (some excerpts)

Pharmaceutical giant AstraZeneca announced on the 15th that the US Food and Drug Administration (FDA) has designated the company's cancer treatment drug “imifinge” as a treatment for localized small cell lung cancer with a very high degree of malignancy even among lung cancers as a priority examination target.
On the London stock market, AstraZeneca hit a new high since listing for 4 consecutive business days. The stock price was 130.48 pounds, and the total market value reached about 2020 billion pounds (about 2590 dollars), solidifying the top position in the London market.
According to AstraZeneca, the FDA is expected to decide whether to approve it in the fourth quarter.
Imifinge has recently been designated by the FDA as a revolutionary therapeutic agent for the treatment of small cell lung cancer, and the view was expressed that it would lead to an acceleration of the examination.